Centocor
This article was originally published in The Gray Sheet
Executive Summary
Monoclonal antibody platelet glycoprotein IIb/IIIa inhibitor ReoPro with stenting reduces risk of death or heart attack by 51% at six-months compared to use of stents alone, according to results released from the EPISTENT trial. The 2,399 patient, 63-center trial, primarily using J&J's Palmaz-Schatz stent, randomized patients with ischemic heart disease to either stenting with placebo, stenting with ReoPro or angioplasty with ReoPro. A sustained six-month 31% reduction in death and heart attack also was shown using ReoPro and angioplasty compared to stenting alone
You may also be interested in...
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.
Report Finds Digital Diabetes Tools Deliver No ‘Meaningful Clinical Benefits'
A new report from health economics group the Peterson Health Technology Institute found that apps to help patients manage their blood sugar levels delivered few of the promised benefits. However, a digital therapeutics industry association says PHTI’s research cast too narrow a net.
Merck’s Winrevair Well Positioned To Benefit From Medicare Part D Redesign
Significant cost sharing reductions under the redesign will enhance uptake of the pulmonary arterial hypertension drug. The trade-off is a 20% mandatory price discount in the catastrophic phase.